Study in healthy male participants to compare the blood levels after epoetin alfa (Blau EPO) and Erypo, administered as multiple intravenous injections as well as safety, tolerability and the effects on certain blood values.

2025-522246-43-00 Protocol EPOBLAMD25013 Human pharmacology (Phase I) - Other Authorised, recruitment pending

Status Authorised, recruitment pending · 1 EU/EEA countries · 1 sites · Protocol EPOBLAMD25013

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Authorised, recruitment pending
Participants planned 124
Countries 1
Sites 1

Treatment of symptomatic anemia associated with chronic renal failure:

Key facts

Sponsor
Blau Farmaceutica S.A.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male
Therapeutic area
Diseases [C] - Hemic and Lymphatic Diseases [C15]
Decision date (initial)
2026-04-02
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Treatment of symptomatic anemia associated with chronic renal failure:

VersionLevelCodeTermSystem organ class
20.0 LLT 10058132 Renal anemia 10005329

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Blau Farmaceutica S.A.

2 Total trials
Commercial
Sponsor organisation
Blau Farmaceutica S.A.
Address
Rodovia Raposo Tavares Km 30 5, Jardim Dinorah Jardim Dinorah
City
Cotia
Postcode
06703-030
Country
Brazil

Scientific contact point

Organisation
Blau Farmaceutica S.A.
Contact name
Clinical Research team

Public contact point

Organisation
Blau Farmaceutica S.A.
Contact name
Clinical Research team

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Authorised, recruitment pending 124 1
Rest of world 0

Investigational sites

Germany

1 site · Authorised, recruitment pending
Nuvisan GmbH
Clinical Services, Wegenerstrasse 13, Ludwigsfeld, Neu-Ulm

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2026-02-05 Germany Acceptable with conditions
2026-04-01
2026-04-02